Insulin-like growth factor 1 mediates negative feedback to somatotroph GH expression via POU1F1/CREB binding protein interactions

Molecular and Cellular Biology

Volumn 32, Issue 21, 2012, Pages 4258-4269

  Romero, Christopher J ^a   Pine Twaddell, Elyse ^a,b   Sima, Daniela I ^a,c   Miller, Ryan S ^a   He, Ling ^a   Wondisford, Fredric ^a   Radovick, Sally ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c ALBANY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; MESSENGER RNA; MUTANT PROTEIN; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; TRANSCRIPTION FACTOR PIT 1;

ANIMAL EXPERIMENT; ARTICLE; BODY FAT; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE RELEASE; HORMONAL REGULATION; INTRACELLULAR SIGNALING; MALE; MOUSE; NEGATIVE FEEDBACK; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; WEIGHT GAIN; WESTERN BLOTTING;

ADIPOSE TISSUE; ANIMALS; BODY COMPOSITION; CELL LINE; CHROMONES; CREB-BINDING PROTEIN; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; FEEDBACK, PHYSIOLOGICAL; FLAVONOIDS; GENE KNOCK-IN TECHNIQUES; GENOTYPE; GROWTH HORMONE; GROWTH HORMONE-RELEASING HORMONE; INSULIN-LIKE GROWTH FACTOR I; MICE; MICE, INBRED C57BL; MITOGEN-ACTIVATED PROTEIN KINASES; MORPHOLINES; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; RATS; RNA, MESSENGER; SIGNAL TRANSDUCTION; SOMATOTROPHS; TRANSCRIPTION FACTOR PIT-1; WEIGHT GAIN;

MUS;

EID: 84868702097     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.00171-12     Document Type: Article

References (56)

1. Alessi DR, Cuenda A, Cohen P, Dudley DT, Saltiel AR. 1995. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J. Biol. Chem. 270:27489-27494.
2. Anderson LL, Jeftinija S, Scanes CG. 2004. Growth hormone secretion: molecular and cellular mechanisms and in vivo approaches. Exp. Biol. Med. (Maywood) 229:291-302.
3. Arias J, et al. 1994. Activation of cAMP and mitogen responsive genes relies on a common nuclear factor. Nature 370:226-229. doi:10.1038/ 370226a0.
4. Balcombe JP, Barnard ND, Sandusky C. 2004. Laboratory routines cause animal stress. Contemp. Top. Lab. Anim. Sci. 43:42-51.
5. Barinaga M, et al. 1983. Transcriptional regulation of growth hormone gene expression by growth hormone-releasing factor. Nature 306:84-85.
6. Barkan AL, Beitins IZ, Kelch RP. 1988. Plasma insulin-like growth factor-I/somatomedin-C in acromegaly: correlation with the degree of growth hormone hypersecretion. J. Clin. Endocrinol. Metab. 67:69-73.
7. Berelowitz M, et al. 1981. Somatomedin-C mediates growth hormone negative feedback by effects on both the hypothalamus and the pituitary. Science 212:1279-1281.
8. Bilezikjian LM, Vale WW. 1983. Stimulation of adenosine 3=,5=- monophosphate production by growth hormone-releasing factor and its inhibition by somatostatin in anterior pituitary cells in vitro. Endocrinol- ogy 113:1726-1731.
9. Bodner M, et al. 1988. The pituitary-specific transcription factor GHF-1 is a homeobox-containing protein. Cell 55:505-518.
10. Bodner M, Karin M. 1987. A pituitary-specific trans-acting factor can stimulate transcription from the growth hormone promoter in extracts of nonexpressing cells. Cell 50:267-275.
11. Bustin SA, Benes V, Nolan T, Pfaffl MW. 2005. Quantitative real-time RT-PCR-a perspective. J. Mol. Endocrinol. 34:597-601. doi:10.1677/ jme.1.01755.
12. Castillo AI, Aranda A. 1997. Differential regulation of pituitary-specific gene expression by insulin-like growth factor 1 in rat pituitary GH4C1 and GH3 cells. Endocrinology 138:5442-5451.
13. Chitnis MM, Yuen JS, Protheroe AS, Pollak M, Macaulay VM. 2008. The type 1 insulin-like growth factor receptor pathway. Clin. Cancer Res. 14:6364-6370. doi:10.1158/1078-0432.CCR-07-4879.
14. Clark RG, Carlsson LM, Robinson IC. 1988. Growth hormone (GH) secretion in the conscious rat: negative feedback of GH on its own release. J. Endocrinol. 119:201-209.
15. Cohen LE, Hashimoto Y, Zanger K, Wondisford F, Radovick S. 1999. CREB-independent regulation by CBP is a novel mechanism of human growth hormone gene expression. J. Clin. Invest. 104:1123-1130. doi: 10.1172/JCI7308.
16. Datta SR, et al. 1997. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91:231-241.
17. Dudek H, et al. 1997. Regulation of neuronal survival by the serine- threonine protein kinase Akt. Science 275:661-665.
18. Fox SR, et al. 1990. The homeodomain protein, Pit-1/GHF-1, is capable of binding to and activating cell-specific elements of both the growth hormone and prolactin gene promoters. Mol. Endocrinol. 4:1069-1080.
19. He L, et al. 2009. Metformin and insulin suppress hepatic gluconeogen- esis throughphosphorylation of CREB binding protein. Cell 137:635- 646. doi:10.1016/j.cell.2009.03.016.
20. Ingraham HA, et al. 1990. The POU-specific domain of Pit-1 is essential for sequence-specific, high affinity DNA binding and DNA-dependent Pit-1-Pit-1 interactions. Cell 61:1021-1033.
21. Inoue K, et al. 1990. Establishment of a series of pituitary clonal cell lines differing in morphology, hormone secretion, and response to estrogen. Endocrinology 126:2313-2320.
22. Jones JI, Clemmons DR. 1995. Insulin-like growth factors and their binding proteins: biological actions. Endocr. Rev. 16:3-34.
23. Kishimoto M, et al. 2002. Novel function of the transactivation domain of a pituitary-specific transcription factor, Pit-1. J. Biol. Chem. 277:45141- 45148. doi:10.1074/jbc.M202991200.
24. Kulik G, Klippel A, Weber MJ. 1997. Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt. Mol. Cell. Biol. 17:1595-1606.
25. Kwok RP, et al. 1994. Nuclear protein CBP is a coactivator for the tran- scription factor CREB. Nature 370:223-226. doi:10.1038/370223a0.
26. LeRoith D. 2000. Insulin-like growth factor I receptor signaling- overlapping or redundant pathways? Endocrinology 141:1287-1288.
27. Liao L, et al. 2006. Liver-specific overexpression of the insulin-like growth factor-I enhances somatic growth and partially prevents the effects of growth hormone deficiency. Endocrinology 147:3877-3888. doi: 10.1210/en.2005-1537
28. Lipkin SM, Naar AM, Kalla KA, Sack RA, Rosenfeld MG. 1993. Iden- tification of a novel zinc finger protein binding a conserved element crit- ical for Pit-1-dependent growth hormone gene expression. Genes Dev. 7:1674-1687.
29. Lira SA, Kalla KA, Glass CK, Drolet DW, Rosenfeld MG. 1993. Syner- gistic interactions between Pit-1 and other elements are required for ef- fective somatotroph rat growth hormone gene expression in transgenic mice. Mol. Endocrinol. 7:694-701.
30. Mathews LS, et al. 1988. Growth enhancement of transgenic mice ex- pressing human insulin-like growth factor I. Endocrinology 123:2827- 2833.
31. Morishita M, et al. 2003. The effects of GH-releasing hormone/ somatostatin on the 5=-promoter activity of the GH gene in vitro. J. Mol. Endocrinol. 31:441-448.
32. Nelson C, Albert VR, Elsholtz HP, Lu LI, Rosenfeld MG. 1988. Activa- tion of cell-specific expression of rat growth hormone and prolactin genes by a common transcription factor. Science 239:1400-1405.
33. Niiori-Onishi A, et al. 1999. Molecular mechanisms of the negative effect of insulin-like growth factor-I on growth hormone gene expression in MtT/S somatotroph cells. Endocrinology 140:344-349.
34. Párrizas M, Saltiel AR, LeRoith D. 1997. Insulin-like growth factor 1 inhibits apoptosis using the phosphatidylinositol 3=-kinase and mitogen- activated protein kinase pathways. J. Biol. Chem. 272:154-161.
35. Romero CJ, et al. 2010. Targeted deletion of somatotroph insulin-like growth factor-I signaling in a cell-specific knockout mouse model. Mol. Endocrinol. 24:1077-1089. doi:10.1210/me.2009-0393.
36. Rosenfeld MG. 1991. POU-domain transcription factors: pou-er-ful de- velopmental regulators. Genes Dev. 5:897-907.
37. Schaufele F, West BL, Baxter JD. 1992. Synergistic activation of the rat growth hormone promoter by Pit-1 and the thyroid hormone receptor. Mol. Endocrinol. 6:656-665.
38. Schindler WJ, Hutchins MO, Septimus EJ. 1972. Growth hormone secretion and control in the mouse. Endocrinology 91:483-490.
39. Schwander JC, Hauri C, Zapf J, Froesch ER. 1983. Synthesis and secre- tion of insulin-like growth factor and its binding protein by the perfused rat liver: dependence on growth hormone status. Endocrinology 113:297- 305.
40. Sugihara H, et al. 1999. Effect of insulin-like growth factor-I on growth hormone-releasing factor receptor expression in primary rat anterior pituitary cell culture. Neurosci. Lett. 276:87-90.
41. Sun P, Maurer RA. 1995. An inactivating point mutation demonstrates that interaction of cAMP response element binding protein (CREB) with the CREB binding protein is not sufficient for transcriptional activation. J. Biol. Chem. 270:7041-7044.
42. Tamaki M, Sato M, Niimi M, Takahara J. 1995. Resistance of growth hormone secretion to hypoglycemia in the mouse. J. Neuroendocrinol. 7:371-376.
43. Tannenbaum GS, Guyda HJ, Posner BI. 1983. Insulin-like growth fac- tors: a role in growth hormone negative feedback and body weight regu- lation via brain. Science 220:77-79.
44. Theill LE, Castrillo JL, Wu D, Karin M. 1989. Dissection of functional domains of the pituitary-specific transcription factor GHF-1. Nature 342: 945-948. doi:10.1038/342945a0.
45. Thorner MO, et al. 1990. Physiological role of somatostatin on growth hormone regulation in humans. Metabolism 39:40-42.
46. Turyn D, Bartke A. 1993. Pharmacokinetics of radioiodinated human and ovine growth hormones in transgenic mice expressing bovine growth hormone. Transgenic Res. 2:219-226.
47. Vance ML. 1990. Growth-hormone-releasing hormone. Clin. Chem. 36: 415-420.
48. Vlahos CJ, Matter WF, Hui KY, Brown RF. 1994. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1- benzopyran-4-one (LY294002). J. Biol. Chem. 269:5241-5248.
49. Wallenius K, et al. 2001. Liver-derived IGF-I regulates GH secretion at the pituitary level in mice. Endocrinology 142:4762-4770.
50. Xu J, et al. 2011. Exploring endocrine GH pattern in mice using rank plot analysis and random blood samples. J. Endocrinol. 208:119-129. doi: 10.1677/JOE-10-0317.
51. Yakar S, et al. 1999. Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc. Natl. Acad. Sci. U. S. A. 96: 7324-7329.
52. Yamasaki H, Prager D, Gebremedhin S, Moise L, Melmed S. 1991. Binding and action of insulin-like growth factor I in pituitary tumor cells. Endocrinology 128:857-862.
53. Yamashita S, Melmed S. 1986. Insulin-like growth factor I action on rat anterior pituitary cells: suppression of growth hormone secretion and messenger ribonucleic acid levels. Endocrinology 118:176-182.
54. Yamashita S, Melmed S. 1987. Insulinlike growth factor I regulation of growth hormone gene transcription in primary rat pituitary cells. J. Clin. Invest. 79:449-452. doi:10.1172/JCI112832.
55. Zanger K, Radovick S, Wondisford FE. 2001. CREB binding protein recruitment to the transcription complex requires growth factor- dependent phosphorylation of its GF box. Mol. Cell 7:551-558.
56. Zhou XY, et al. 2004. Insulin regulation of hepatic gluconeogenesis through phosphorylation of CREB-binding protein. Nat. Med. 10:633- 637. doi:10.1038/nm1050.